Compare Amphastar Pharmaceuticals Inc (AMPH) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs United Microelectronics Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while United Microelectronics Corp trades at $19.03 (market cap $47.80B). The key difference: United Microelectronics Corp is far larger — about 55.3× Amphastar Pharmaceuticals Inc's market cap, and United Microelectronics Corp pays a 2.13% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | UMC | |
|---|---|---|
Market Cap | $863.95M | $47.80B |
Sector | Health | Technology |
52-Week High | $30.81 | $28.02 |
52-Week Low | $16.87 | $6.58 |
Enterprise Value | $1.26B | $44.92B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
UMC trades at $18.72, down 2.5% today, amid a bearish technical signal with key resistance at $19. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.54 vs. $0.16 expected, and announced fab expansions in Singapore and Taiwan to meet AI-driven demand. Revenue growth is projected to rise to $250.7B in 2026, with a net income margin of 32.75%, though profit margins have declined from 2022 peaks. Analyst sentiment is mixed, with 26.7% buy ratings but a majority hold consensus.
The outlook for UMC is cautiously optimistic, driven by AI expansion and solid profitability, but risks include competitive pressures and margin compression. Near-term price action hinges on breaking resistance at $19, with support at $18. Institutional activity shows mixed positioning, reflecting uncertainty over execution amid capital expenditure increases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
